<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00613054</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00000393</org_study_id>
    <nct_id>NCT00613054</nct_id>
  </id_info>
  <brief_title>Ph I Zactima + Imatinib Mesylate &amp; Hydroxyurea for Pts w Recurrent Malignant Glioma</brief_title>
  <official_title>Phase I Study of Zactima (ZD6474) Plus Imatinib Mesylate and Hydroxyurea for Patients With Recurrent Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annick Desjardins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective To determine maximum tolerated dose &amp; dose limiting toxicity of Zactima&#xD;
      when combined w standard dosing of imatinib mesylate &amp; hydroxyurea among pts w recurrent&#xD;
      malignant glioma who are on &amp; not on enzyme-inducing anti-epileptic drugs Secondary&#xD;
      Objectives To assess safety &amp; tolerability of Zactima + imatinib mesylate &amp; hydroxyurea To&#xD;
      evaluate pharmacokinetics of Zactima among MG pts on &amp; not on enzyme inducing anti-epileptic&#xD;
      drugs (EIAEDs) when combo w imatinib mesylate &amp; hydroxyurea To evaluate pharmacokinetics of&#xD;
      imatinib mesylate among MG pts on &amp; not on EIAEDs when combo w Zactima &amp; hydroxyurea&#xD;
      Exploratory Objective To evaluate for evidence of anti-tumor activity of study regimen among&#xD;
      recurrent malignant glioma (RMG) pts including radiographic response rate, 6-month&#xD;
      progression free survival (PFS) rate &amp; median PFS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      vascular endothelial growth factor (VEGF) angiogenic &amp; Phosphoinositide 3-kinase&#xD;
      inhibitor/Protein Kinase B (PI3K/AKT) mitogenic cascades are 2 upregulated cell signalling&#xD;
      pathways in MG that contribute to several hallmark phenotypic features of these tumors.&#xD;
      Regimen of Zactima + imatinib mesylate represents novel anti-glioma strategy because it&#xD;
      targets 3 key mediators of dysregulated cell signalling involving VEGF &amp; PI3K-AKT pathways&#xD;
      including VEGFR, epidermal growth factor receptor (EGFR) &amp; platelet derived growth&#xD;
      factor(PDGFR). Furthermore by combining Zactima w imatinib mesylate, VEGF &amp; PI3-k/AKT&#xD;
      pathways can potentially inhibit multiple mediators of each of these pathways. Regarding&#xD;
      PI3-K/AKT signalling, regimen can inhibit activation of EGFR &amp; PDGFR. Regarding VEGF&#xD;
      signalling, regimen has potential to inhibit 3 components of VEGFR directed angiogenesis.&#xD;
      1st, Zactima can directly inhibit VEGFR activation. 2nd, both Zactima &amp; imatinib mesylate can&#xD;
      indirectly decrease activity of VEGF pathway by diminishing positive input from activated&#xD;
      PI3-K/AKT signalling. 3rd, imatinib mesylate may inhibit PDGF-regulated pericyte maturation&#xD;
      of tumor blood vessels.&#xD;
&#xD;
      We have previously demonstrated that regimen of imatinib mesylate + hydroxyurea is active&#xD;
      regimen among recurrent glioblastoma multiforme (GBM) pts. Furthermore this activity appears&#xD;
      substantially better than that reported for imatinib mesylate alone. Although mechanism of&#xD;
      enhanced activity for imatinib mesylate when combo w hydroxyurea is unclear, it is logical to&#xD;
      build upon combo of imatinib mesylate + hydroxyurea in subsequent studies rather than&#xD;
      imatinib mesylate alone. Current study will therefore determine MTD of Zactima when combo w&#xD;
      standard doses of imatinib mesylate &amp; hydroxyurea among RMG pts. Ph II study will then be&#xD;
      performed, incorporating maximum tolerated dose (MTD) of Zactima + imatinib mesylate in order&#xD;
      to evaluate anti-glioma potential of regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine MTD &amp; dose-limiting toxicity (DLT) &amp; Zactima when combo w Imatinib mesylate &amp; Hydroxyurea among pt w Recurrent MG</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To further assess safety &amp; tolerability of Zactima &amp; Imatinib mesylate &amp; Hydroxyurea</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Gliosarcoma</condition>
  <arm_group>
    <arm_group_label>Zactima + Gleevec + Hydrea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zactima, Gleevec, Hydroxyurea</intervention_name>
    <description>Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate &amp; hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs &amp; 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate &amp; that such doses are safe &amp; well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.&#xD;
Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety &amp; pharmacokinetic parameters as required.&#xD;
Treatment cycle is defined as daily administration of Zactima + imatinib mesylate &amp; hydroxyurea for 28 days for purpose of scheduling evaluations.</description>
    <arm_group_label>Zactima + Gleevec + Hydrea</arm_group_label>
    <other_name>Zactima-ZD6474-Vandetanib</other_name>
    <other_name>Gleevec-Imatinib mesylate</other_name>
    <other_name>Hydroxyurea-Droxia-Hydrea-Hydroxycarbamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pts have baseline evaluations performed ≤14days prior to 1st dose of study drug unless&#xD;
             otherwise specified. Written informed consent must be obtained from pt prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Pts w MG who are presenting in 1st, 2nd or 3rd recurrence or relapse&#xD;
&#xD;
          -  Pts may not have tumor biopsy &lt;1 wk or surgical resection &lt;2wks&#xD;
&#xD;
          -  For stratum of non-EIAED pts, each pt be off all EIAEDs for &gt;2 wks prior to starting&#xD;
             study drug; similarly for stratum of EIAED pts, each pt be on EIAED for &gt;2 wks prior&#xD;
             to starting study drug&#xD;
&#xD;
          -  Pts should be on non-increasing dose of steroids for &gt;7 days prior to obtaining&#xD;
             baseline Gd-MRI of brain&#xD;
&#xD;
          -  Pts should be on non-increasing dose of steroids for &gt;7 days prior to starting study&#xD;
             drug&#xD;
&#xD;
          -  Multifocal disease is eligible&#xD;
&#xD;
          -  Age &gt;18yrs&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) of &gt;70&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1.0 x 10 9/L&#xD;
&#xD;
          -  Hgb&gt;g/dL&#xD;
&#xD;
          -  Platelets&gt;100 x 10 9/L&#xD;
&#xD;
          -  Serum creatinine&lt;1.5 x upper limit of normal (ULN)/measured 24hr creatinine clearance&#xD;
             (CrCl) &gt;50 milliliters/min/1.73m&#xD;
&#xD;
          -  Life ≥12wks&#xD;
&#xD;
          -  Written informed consent obtained prior to any screening procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serum bilirubin &gt;1.5x ULN of reference range&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 x Upper Limit of the Reference Range (ULRR)/CrCl &lt;50&#xD;
             milliliters/min&#xD;
&#xD;
          -  K&lt;4.0 mmol/L despite supplementation; serum Ca/Mg out of normal range despite&#xD;
             supplementation&#xD;
&#xD;
          -  alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2.5 x ULRR&#xD;
&#xD;
          -  Evidence of severe/uncontrolled systemic disease or any concurrent condition which in&#xD;
             Investigator's opinion makes it undesirable for pt to participate in trial or which&#xD;
             would jeopardize compliance w protocol&#xD;
&#xD;
          -  Clinically significant cardiac event such as myocardial infarction; New York Heart&#xD;
             Association (NYHA) classification of heart disease &gt;2 within 3 months before&#xD;
             entry;/presence of cardiac disease that, in opinion of Investigator, increases risk of&#xD;
             ventricular arrhythmia or dysfunction; ejection fraction&lt;50 percent prior to study&#xD;
             initiation&#xD;
&#xD;
          -  History of arrhythmia-symptomatic/requires treatment/asymptomatic sustained&#xD;
             ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded&#xD;
&#xD;
          -  Previous history of corrected QT interval (QTc) prolongation as result from other&#xD;
             medication that required discontinuation of that medication&#xD;
&#xD;
          -  Congenital long QT syndrome/1st degree relative with unexplained sudden death under 40&#xD;
             years&#xD;
&#xD;
          -  Presence of left bundle branch block&#xD;
&#xD;
          -  QTc with Bazett's correction that is unmeasurable/&gt;480 msec on screening ECG. If pt&#xD;
             has QTc &gt;480 msec on screening ECG, screen ECG may be repeated twice. Average QTc from&#xD;
             3 screening ECGs must be &lt;480 msec in order for pt to be eligible for study&#xD;
&#xD;
          -  Any concomitant medication that may cause QTc prolongation, induce Torsades de&#xD;
             Pointes/induce cytochrome P450 3A4 (CYP3A4) function except for EIAEDs&#xD;
&#xD;
          -  Hypertension not controlled by medical therapy&#xD;
&#xD;
          -  Currently active diarrhea that may affect ability of pt to absorb study&#xD;
             regimen/tolerate diarrhea&#xD;
&#xD;
          -  Pregnant/breast feeding&#xD;
&#xD;
          -  Previous/current malignancies of other histologies &lt;1yr, w exception of cervical&#xD;
             carcinoma in situ &amp; adequately treated basal cell/squamous cell carcinoma of skin&#xD;
&#xD;
          -  Receipt of any investigational agents within 30 days prior to commencing study&#xD;
             treatment unless pt has recovered from all anticipated toxicities of investigational&#xD;
             agent&#xD;
&#xD;
          -  Last dose of prior chemo discontinued &lt;4 wks before start of study therapy unless pt&#xD;
             has recovered from all anticipated toxicities of chemo&#xD;
&#xD;
          -  Last radiation therapy (XRT) &lt;4wks before start of study therapy, unless pt has&#xD;
             recovered from all anticipated toxicities of XRT&#xD;
&#xD;
          -  Any unresolved toxicity &gt; Common Terminology Criteria (CTC) grade 1 from previous&#xD;
             anti-cancer therapy&#xD;
&#xD;
          -  Previous enrollment/randomization of treatment in present study&#xD;
&#xD;
          -  Major surgery &lt;4 wks/incompletely healed surgical incision before starting study&#xD;
             therapy&#xD;
&#xD;
          -  Pts who have received prior oral VEGFR, EGFR/PDGFR-directed therapies&#xD;
&#xD;
          -  Pts who are taking warfarin sodium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annick Desjardins, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cancer.duke.edu/btc/</url>
    <description>The Preston Robert Tisch Brain Tumor Center at DUKE</description>
  </link>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>January 29, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2008</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Annick Desjardins</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>GBM</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Zactima</keyword>
  <keyword>Gleevec</keyword>
  <keyword>Hydroxyurea</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Gliosarcoma</keyword>
  <keyword>Recurrent malignant glioma</keyword>
  <keyword>ZD6474</keyword>
  <keyword>Malignant glioma</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Droxia</keyword>
  <keyword>Hydrea</keyword>
  <keyword>Hydroxycarbamide</keyword>
  <keyword>Vandetanib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

